These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34243629)

  • 1. Metformin and insulin-resistant related diseases: Emphasis on the role of microRNAs.
    Alimoradi N; Firouzabadi N; Fatehi R
    Biomed Pharmacother; 2021 Jul; 139():111662. PubMed ID: 34243629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer.
    Zhou JY; Xu B; Li L
    Drug Dev Res; 2015 Sep; 76(6):263-9. PubMed ID: 26936407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs and type 2 diabetes mellitus: Molecular mechanisms and the effect of antidiabetic drug treatment.
    Yaribeygi H; Katsiki N; Behnam B; Iranpanah H; Sahebkar A
    Metabolism; 2018 Oct; 87():48-55. PubMed ID: 30253864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Descending Expression of miR320 in Insulin-Resistant Adipocytes Treated with Ascending Concentrations of Metformin.
    Naghiaee Y; Didehdar R; Malekpour-Dehkordi Z; Pourrajab F; Mohiti-Ardakani J
    Biochem Genet; 2020 Oct; 58(5):661-676. PubMed ID: 32367399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of metformin in type II diabetes.
    Epstein S
    Cleve Clin J Med; 1995; 62(5):278-9. PubMed ID: 7586481
    [No Abstract]   [Full Text] [Related]  

  • 8. How metformin affects various malignancies by means of microRNAs: a brief review.
    Alimoradi N; Firouzabadi N; Fatehi R
    Cancer Cell Int; 2021 Apr; 21(1):207. PubMed ID: 33849540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
    Glueck CJ; Goldenberg N; Sieve L; Wang P
    Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved endothelial function with metformin in type 2 diabetes mellitus.
    Mather KJ; Verma S; Anderson TJ
    J Am Coll Cardiol; 2001 Apr; 37(5):1344-50. PubMed ID: 11300445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myths about Insulin Resistance: Tribute to Gerald Reaven.
    Kim SH; Abbasi F
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):47-52. PubMed ID: 30912338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes.
    Adamia N; Virsaladze D; Charkviani N; Skhirtladze M; Khutsishvili M
    Georgian Med News; 2007 Apr; (145):52-5. PubMed ID: 17525501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of metformin regulation in central nervous system: Progression and future perspectives.
    Cao G; Gong T; Du Y; Wang Y; Ge T; Liu J
    Biomed Pharmacother; 2022 Dec; 156():113686. PubMed ID: 36244266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
    Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
    Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients.
    Steffensen LB; Feddersen S; Preil SR; Rasmussen LM
    Cardiovasc Diabetol; 2018 May; 17(1):72. PubMed ID: 29773082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic switching in the hypoglycemic and antitumor effects of metformin on high glucose induced HepG2 cells.
    Lv Y; Tian N; Wang J; Yang M; Kong L
    J Pharm Biomed Anal; 2018 Jul; 156():153-162. PubMed ID: 29705631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice.
    Yoon SH; Han EJ; Sung JH; Chung SH
    Biol Pharm Bull; 2007 Nov; 30(11):2196-200. PubMed ID: 17978500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells.
    Lee SK; Lee JO; Kim JH; Kim SJ; You GY; Moon JW; Jung JH; Park SH; Uhm KO; Park JM; Suh PG; Kim HS
    J Cell Biochem; 2011 May; 112(5):1259-67. PubMed ID: 21465524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic effects of metformin: From molecular mechanisms to clinical implications.
    Bridgeman SC; Ellison GC; Melton PE; Newsholme P; Mamotte CDS
    Diabetes Obes Metab; 2018 Jul; 20(7):1553-1562. PubMed ID: 29457866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin improves vascular function in insulin-resistant rats.
    Katakam PV; Ujhelyi MR; Hoenig M; Miller AW
    Hypertension; 2000 Jan; 35(1 Pt 1):108-12. PubMed ID: 10642283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.